Equitech-Bio

Equitech-Bio

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $25.2M

Overview

Equitech-Bio is a young but strategically positioned reagent supplier in the biologics research sector, leveraging over 30 years of industry experience (implied from website content) to provide a broad portfolio of animal-derived products. The company operates a B2B e-commerce platform, offering over 500 products including albumins, animal sera/plasma, IgG, and antisera, with a stated focus on quality, competitive pricing, and customer service. While not a therapeutic developer, it serves as a critical enabler for preclinical research, diagnostics development, and biologics manufacturing across academia and industry. Its rapid catalog expansion and customer-centric model suggest a focus on capturing market share in the specialized research reagents space.

BiologicsAntibodies

Technology Platform

Specialized collection, processing, and purification of animal-derived biological materials (plasma, serum, albumins, IgG) from over 16 species for research and diagnostic applications.

Funding History

2
Total raised:$25.2M
Series A$22M
Seed$3.2M

Opportunities

Growing demand for specialized, species-specific research reagents beyond standard models presents a niche market.
Cost-conscious academic and biotech labs may be drawn to a value-priced alternative to large, established suppliers.
Expansion into value-added formats or custom biological services could increase margins.

Risk Factors

Heavy reliance on volatile animal agriculture supply chains for raw materials.
Intense competition from large, well-capitalized multinational life science suppliers.
Reputational and financial risk from any quality control failure or contamination in biological products.

Competitive Landscape

Competes directly with large life science tools conglomerates (e.g., Thermo Fisher Scientific, MilliporeSigma) and specialized reagent suppliers (e.g., Jackson ImmunoResearch, Cedarline). Differentiation is based on broad species variety, competitive pricing, and customer service, rather than proprietary technology.